1.Russo AF. Calcitonin Gene-Related Peptide (CGRP): A New Target for Migraine. ANNU REV PHARMACOL 2015; 55:533–552
2.Russo A, Coppola G, Pierelli F, et al. Pain Perception and Migraine. FRONT NEUROL 2018;9
3.Schuster NM, Rapoport AM. New strategies for the treatment and prevention of primary headache disorders. NAT REV NEUROL 2016; 12:635–650
4.Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. NEUROLOGY 2008; 71:848–855
5.Edvinsson L. The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine. HEADACHE 2017;57 Suppl 2:47–55
6.Zhu Y, Liu Y, Zhao J, et al. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis. NEUROL SCI 2018;39:2097–2106
7.Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. LANCET 2018; 392:2280–2287
8.Dodick DW, Ashina M, Brandes JL, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. CEPHALALGIA 2017;38:1026–1037
9.Dodick DW, Silberstein SD, Bigal ME, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA 2018; 319:1999–2008
10.Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE–1 Randomized Clinical Trial. JAMA NEUROL 2018; 75:1080–1088
11.Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE–2 Phase 3 randomized controlled clinical trial. CEPHALALGIA 2017; 38:1442–1454
12.The International Classification of Headache Disorders, 3rd edition (beta version). CEPHALALGIA 2013; 33:629–808
13.Goadsby PJ, Reuter U, Hallstrom Y, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 2017; 377:2123–2132
14.Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. LANCET NEUROL 2016; 15:382–390
15.Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. LANCET NEUROL 2014; 13:1100–1107
16.Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV–48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. LANCET NEUROL 2015;14:1081–1090
17.Skljarevski V, Oakes TM, Zhang Q, et al. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial. JAMA NEUROL 2018; 75:187–193
18.Dodick DW, Goadsby PJ, Spierings EL, et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. LANCET NEUROL 2014;13:885–892
19.Silberstein SD, Kudrow D, Saper J, et al. Eptinezumab Results for the Prevention of Episodic Migraine over One Year in the PROMISE–1 (PRevention of Migraine via Intravenous Eptinezumab Safety and efficacy–1) Trial. HEADACHE 2018;58:1298
20.Hong P, Wu X, Liu Y. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis. Clin Neurol Neurosurg 2017;154:74–78
21.Xu D, Chen D, Zhu L, et al. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine—a meta-analysis of randomized controlled trials. CEPHALALGIA 2019:1524364876
22.Lattanzi S, Brigo F, Trinka E, et al. Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety. DRUGS 2019
23.Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. NAT REV NEUROL 2018; 14:338–350
24.Gonzalez-Hernandez A, Marichal-Cancino BA, MaassenVanDenBrink A, Villalon CM. Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opin Drug Metab Toxicol 2018;14:25–41
25.Bell IM. Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine. J MED CHEM 2014;57:7838–7858